# A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

> **NCT01455870** · PHASE3 · COMPLETED · sponsor: **Intarcia Therapeutics** · enrollment: 535 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ITCA 650 60 mcg/day
- **DRUG:** sitagliptin

## Key facts

- **NCT ID:** NCT01455870
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01455870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01455870, "A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01455870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*